March 2023

Bellvitge Hospital and IDIBELL lead clinical trial to reduce the impact of infections in heart transplant patients

It is a project that delves into personalized medicine. This trial has been financed by the Carlos III Health Institute through R&D projects call in 2019, and by a grant from the Spanish Society of Cardiology.

Consumption of processed foods increases the risk of cancer

This is the largest and most complete study carried out on the subject, it has included more than 450,000 people from 9 European countries and has analyzed the relationship of diet with 25 different types of cancer. The work concludes that replacing 10% of the intake of processed products with others that are not reduces the risk of suffering any type of cancer.

IDIBELL’s technology, licensed to LoopDx, starts a crowdequity campaign

Between 2018 and 2019, the IDIBELL and Bellvitge University Hospital researcher Joan Sabater, in collaboration with the start-up LoopDx, developed SeptiLoop, a rapid sepsis diagnostic kit. The result of this project was patented and licensed to the company itself.

Presentation of the new cell sorter of the flow cytometry platform

The Flow Cytometry Platform of the IDIBELL Scientific-Technical Services incorporated new high-performance equipment. It is the Beckman Coulter CytoFLEX SRT Benchtop Cell Separator. The arrival of this state-of-the-art equipment covers the need to renew the cell separation service and makes new and current technological improvements available to researchers. CytoFLEX SRT can meet the requirements for …

Presentation of the new cell sorter of the flow cytometry platform Read More »

Study describes the structural and functional effects of several mutations on the androgen receptor

The androgen receptor is the main target in the fight against prostate cancer. The study, published in the journal Science Advances, states that the analyzed mutations affect several functional regions of the union domain of the androgen receptor to testosterone.

Scroll to Top